Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

10.48
+0.29002.85%
Post-market: 10.480.00000.00%16:38 EDT
Volume:2.71M
Turnover:28.31M
Market Cap:1.91B
PE:-102.74
High:10.60
Open:10.15
Low:10.07
Close:10.19
52wk High:11.33
52wk Low:5.25
Shares:182.32M
Float Shares:172.57M
Volume Ratio:1.04
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1020
EPS(LYR):0.0032
ROE:-617.16%
ROA:6.13%
PB:-196.29
PE(LYR):3,267.85

Loading ...

Jul 30, 2021

Business Combinations

425 - Prospectuses and communications, business combinations
Jul 29, 2021

Major Issues Report

8-K - Current report
Jul 29, 2021

Business Combinations

425 - Prospectuses and communications, business combinations
Jul 28, 2021

Correspondence

CORRESP [Cover] - Correspondence
Jul 19, 2021

Major Issues Report

8-K - Current report
Jul 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jun 08, 2021

Major Issues Report

8-K - Current report
May 25, 2021

Business Combinations

425 - Prospectuses and communications, business combinations
May 24, 2021

Business Combinations

425 - Prospectuses and communications, business combinations
May 24, 2021

Business Combinations

425 - Prospectuses and communications, business combinations
May 24, 2021

Major Issues Report

8-K - Current report
May 24, 2021

Business Combinations

425 - Prospectuses and communications, business combinations
May 13, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2021

Major Issues Report

8-K - Current report
May 06, 2021

Major Issues Report

8-K - Current report
Mar 17, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Mar 11, 2021

Major Issues Report

8-K - Current report
Mar 09, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Mar 09, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 09, 2021

Major Issues Report

8-K - Current report